These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20107156)

  • 1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.
    Piñana JL; Martino R; Gayoso J; Sureda A; de la Serna J; Díez-Martín JL; Vazquez L; Arranz R; Tomás JF; Sampol A; Solano C; Delgado J; Sierra J; Caballero D;
    Haematologica; 2010 Jul; 95(7):1176-82. PubMed ID: 20107156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
    Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
    Tomblyn MR; Ewell M; Bredeson C; Kahl BS; Goodman SA; Horowitz MM; Vose JM; Negrin RS; Laport GG
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):1051-7. PubMed ID: 21073974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.
    Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Busque L; Ahmad I; Roy J
    Biol Blood Marrow Transplant; 2012 Jun; 18(6):951-7. PubMed ID: 22155507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Sureda A; Canals C; Arranz R; Caballero D; Ribera JM; Brune M; Passweg J; Martino R; Valcárcel D; Besalduch J; Duarte R; León A; Pascual MJ; García-Noblejas A; López Corral L; Xicoy B; Sierra J; Schmitz N
    Haematologica; 2012 Feb; 97(2):310-7. PubMed ID: 21993674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
    Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
    Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
    Ono Y; Mori T; Kato J; Yamane A; Shimizu T; Kikuchi T; Kohashi S; Okamoto S
    Am J Hematol; 2012 Sep; 87(9):929-31. PubMed ID: 22674621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
    Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
    Hari P; Carreras J; Zhang MJ; Gale RP; Bolwell BJ; Bredeson CN; Burns LJ; Cairo MS; Freytes CO; Goldstein SC; Hale GA; Inwards DJ; Lemaistre CF; Maharaj D; Marks DI; Schouten HC; Slavin S; Vose JM; Lazarus HM; van Besien K
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):236-45. PubMed ID: 18215784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial.
    Fasslrinner F; Schetelig J; Burchert A; Kramer M; Trenschel R; Hegenbart U; Stadler M; Schäfer-Eckart K; Bätzel M; Eich H; Stuschke M; Engenhart-Cabillic R; Krause M; Dreger P; Neubauer A; Ehninger G; Beelen D; Berdel WE; Siepmann T; Stelljes M; Bornhäuser M
    Lancet Haematol; 2018 Apr; 5(4):e161-e169. PubMed ID: 29550384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
    Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):345-355.e7. PubMed ID: 31014757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy.
    Khouri IF; Lee MS; Romaguera J; Mirza N; Kantarjian H; Korbling M; Albitar M; Giralt S; Samuels B; Anderlini P; Rodriguez J; von Wolff B; Gajewski J; Cabanillas F; Champlin R
    Ann Oncol; 1999 Nov; 10(11):1293-9. PubMed ID: 10631455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.
    Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Laport GG; Montoto S; Maloney DG; Lazarus HM
    Biol Blood Marrow Transplant; 2013 May; 19(5):746-53. PubMed ID: 23380340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.
    Yano S; Mori T; Kanda Y; Kato J; Nakaseko C; Fujisawa S; Tomita N; Sakai R; Shono K; Saitoh T; Aotsuka N; Kobayashi N; Saito T; Takahashi S; Kanamori H; Okamoto S;
    Bone Marrow Transplant; 2015 Oct; 50(10):1299-305. PubMed ID: 26168068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
    Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.